Table 3.
Immunosuppressive regimens in patients with the CMV serostatus “donor and recipient seronegative” and in patients with the CMV serostatus “donor and/or recipient seropositive”
| Parameter | ||||
|---|---|---|---|---|
| Entire cohort (n = 337) | CMV serostatus donor negative/recipient negative (n = 115) | CMV serostatus donor and/or recipient positive (n = 222) | p value | |
| Initial immunosuppressive regimen1 | ||||
| Desensitization procedure, n (%) | 13 (3.86) | 2 (1.74) | 11 (4.95) | 0.232# |
| IL-2R antibody induction, n (%) | 145 (43.0) | 42 (36.5) | 103 (46.4) | 0.104 |
| Thymoglobulin, n (%) | 25 (7.42) | 6 (5.22) | 19 (8.56) | 0.381# |
| Tacrolimus, n (%) | 269 (79.8) | 88 (76.5) | 181 (81.5) | 0.346 |
| Mycophenolate mofetil, n (%) | 293 (86.9) | 102 (88.7) | 191 (86.0) | 0.606 |
| Azathioprine, n (%) | 28 (8.31) | 6 (5.22) | 22 (9.91) | 0.152# |
| Glucocorticoids, n (%) | 328 (97.3) | 111 (96.5) | 217 (97.7) | 0.497 |
| Maintenance immunosuppressive regimen2 | ||||
| Tacrolimus, n (%) | 267 (79.2) | 87 (75.7) | 180 (81.1) | 0.269 |
| Mycophenolate mofetil, n (%) | 256 (76.0) | 89 (77.4) | 167 (75.2) | 0.812 |
| Azathioprine, n (%) | 28 (8.31) | 7 (6.09) | 21 (9.46) | 0.405# |
| Glucocorticoids, n (%) | 283 (84.0) | 96 (83.5) | 187 (84.2) | 0.909 |
IL-2R interleukin 2 receptor
1Until day 30 posttransplant
2At 12 months posttransplant
The respective frequencies of the immunosuppressive regimens between the two patient cohorts were compared by Chi-square test or Fisher’s exact test (marked by #)